Graphite Bio, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kimberlee Cobleigh Drapkin CPA
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 201 Haskins Way South San Francisco CA United States of America 94080
- IPO Date
- Jun 25, 2021
- CIK
- 0001815776
- Website
- graphitebio.com
- Similar Companies
- Business
- Graphite Bio, Inc. (GRPH) operates as a clinical-stage biotechnology company transformed through its merger with LENZ Therapeutics, now focusing on the development and commercialization of ophthalmic solutions for presbyopia treatment; its primary product is VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine-based eye drop targeting near vision loss in an estimated 128 million U.S. patients and 1.8 billion globally. The company leverages its pipeline of investigational therapies, previously centered on gene editing technologies via the proprietary Graphite Platform for precise DNA modifications in hematopoietic stem cells to address single-gene disorders including sickle cell disease (lead candidate GPH101 or nulabeglogene autogedtemcel), beta-thalassemia (GRPH-002), X-linked severe combined immunodeficiency, and Gaucher disease; these efforts have been discontinued post-merger to prioritize presbyopia assets. Founded in 2019 and headquartered in San Diego, California, with all long-lived assets in the United States, Graphite Bio serves the biotechnology and ophthalmology sectors targeting patients with serious genetic diseases and age-related vision impairment. In March 2024, Graphite Bio completed its merger with Lenz Therapeutics, accompanied by a $53.5 million private placement from investors including Versant Ventures, RA Capital Management, and RTW Investments, yielding approximately $210 million in cash for commercialization infrastructure; this transaction followed a special cash dividend to Graphite shareholders and a strategic pivot from gene editing programs, with LENZ advancing Phase 3 CLARITY trial topline results and NDA submission for LNZ100/LNZ101 presbyopia drops in mid-2024. The combined entity, trading under LENZ, maintains operations in the U.S. with no noted subsidiaries or parent relationships, emphasizing regulatory pathways and market expansion for VIZZ.
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
GRAPHITE BIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?